Literature DB >> 15073280

Sticky wickets in lower nephron nephrosis.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15073280      PMCID： PMC1665151          DOI： 10.1113/jphysiol.2004.065086

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  9 in total

Review 1.  Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.

Authors:  Jon T Holmlund
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

2.  Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes.

Authors:  E Mathew; G E Hardee; C F Bennett; K-D Lee
Journal:  Gene Ther       Date:  2003-07       Impact factor: 5.250

Review 3.  Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors.

Authors:  Neelu Kaila; Bert E Thomas
Journal:  Med Res Rev       Date:  2002-11       Impact factor: 12.944

Review 4.  Pharmaceutical prospects for RNA interference.

Authors:  Raymond M Schiffelers; Martin C Woodle; Puthupparampil Scaria
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

5.  Some experiences and problems in treating renal insufficiency: I. Extracorporeal dialysis of the blood in vivo in cases of uremia; 22 treatments on 18 cases. II. Fluid balance problems in cases of acute oliguria; anuria due to acute nephritis, incompatible blood transfusions lower-nephron nephrosis and so on i. a. illustrating the risks of excessive electrolyte-fluid supply and the i. a. illustrating the risks of the modern electrolyte; fluid therapy and the importance of continual weight control.

Authors:  N ALWALL
Journal:  Acta Med Scand Suppl       Date:  1950

6.  Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat.

Authors:  H Haller; D Dragun; A Miethke; J K Park; A Weis; A Lippoldt; V Gross; F C Luft
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

7.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 8.  Inflammatory cell adhesion molecules in ischemic cerebrovascular disease.

Authors:  C J M Frijns; L J Kappelle
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

9.  Effect of antisense oligodeoxynucleotides for ICAM-1 on renal ischaemia-reperfusion injury in the anaesthetised rat.

Authors:  Lik Voon Kiew; Abdul Sattar Munavvar; Chung Hiong Law; Abdullah Nor Azizan; Abdul Rahman Nazarina; Khalifah Sidik; Edward J Johns
Journal:  J Physiol       Date:  2004-03-26       Impact factor: 5.182
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.